RxDoctor Payments Data

Manish Butte

Pediatric Allergy/Immunology · Los Angeles, CANPI 1801861216

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $227,943 of the $356,720 with a category attached, or 63.9%. 22 manufacturers reported payments, led by Grifols USA, LLC at 41.8% of the total. Reporting peaked in 2024 at $88,257 and has fallen 55.9% since, to $38,878 in 2025. Among pediatric allergy/immunology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$356,720in general payments, 2019–2025

Across 418 payments — averaging $853.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Grifols USA, LLC$149K
  • CSL Behring$96K
  • Pharming Healthcare, Inc.$25K
  • Amgen$22K
  • Chiesi USA, Inc.$18K
  • Octapharma USA, Inc.$16K
  • plus $30K from 16 others
$808,489in research payments, 2019–2025

Across 36 payments — averaging $22,458 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Shire North American Group Inc$320K
  • Takeda Pharmaceuticals U.S.A., Inc.$207K
  • Pharming Healthcare, Inc.$159K
  • Chiesi USA, Inc.$59K
  • Swedish Orphan Biovitrum AB$33K
  • Regeneron$31K

What the payments were for

  • Consulting fees$69,50719%
  • Speaking & faculty fees$227,94364%
  • Travel & lodging$44,02112%
  • Food & beverage$15,2394%
  • Education$100%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$356,720 in reported general payments places this provider in the 95th percentile of 48 pediatric allergy/immunology providers in California.

See all pediatric allergy/immunology providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
HizentraImmun Glob G(Igg)/Pro/Iga 0-5017$116,174
Doxycycline Hyclate11$32

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringHizentra$95,606$116,17417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 48 pediatric allergy/immunology providers in California.

Other pediatric allergy/immunology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →